Select year

2026 2025 2024 2023 2022 Earlier

shown/page

10

2025.07.27

ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation
ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation

2025.07.09

A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint
A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint

2025.05.31

ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma
ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma

2025.05.15

Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025
Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025

2025.04.18

CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation
CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation

2025.03.11

AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development
AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development

01
02

Media contact

Media contact

（+86）0755-36993500
pr@juliucq.com